Zacks Investment Research
03 Aug 2026, 23:46 UTC · 1h ago
Jazz Pharmaceuticals (JAZZ) Q2 Earnings Lag Estimates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
03 Aug 2026, 23:46 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Jazz Pharmaceuticals reported quarterly earnings of $5.71 per share, missing the Zacks Consensus Estimate of $6.04 per share. — An earnings miss typically triggers negative short-term price action as it indicates lower-than-expected profitability.
-0.40Jazz Pharmaceuticals reported quarterly revenues of $1.21 billion, exceeding the Zacks Consensus Estimate by 9.33%. — Strong top-line growth and a revenue beat suggest healthy demand for the company's products, partially offsetting the earnings miss.
+0.30Jazz Pharmaceuticals currently holds a Zacks Rank #3 (Hold) based on earnings estimate revisions. — A 'Hold' rating suggests a neutral outlook with no strong catalyst for immediate upward or downward movement.
+0.00Which stocks this story touches
Continue reading
6 related stories
Search tags
The company missed consensus earnings estimates for the quarter, despite beating revenue estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
